No gene in consumer genetics gets searched, blamed and marketed against quite like MTHFR. Depending on which corner of the internet you land in, its common variants explain fatigue, anxiety, miscarriage, heart disease and why you supposedly need a special, more expensive vitamin. The real story is more interesting and much calmer, and it’s a useful case study in how to read any genetic claim.
What the enzyme actually does
MTHFR (methylenetetrahydrofolate reductase) is an enzyme in the folate cycle: it converts one form of folate into the form the body uses to recycle homocysteine into methionine. The famous variant, C677T, swaps one amino acid and makes the enzyme less heat-stable. In the 1995 paper that described it, enzyme activity in people with two copies measured roughly a third of the usual level in laboratory assays.
That is real biochemistry, and it is also extremely common. The CDC’s plain-language page on MTHFR makes the point directly: these variants are common and normal, and in some populations more than one in ten people carry two copies of C677T. A variant carried by that many healthy people cannot, by itself, be a serious malfunction.
Where the hype came from, and what careful reviews found
The early logic was plausible: less enzyme activity can mean higher homocysteine, especially when dietary folate is low, and high homocysteine was associated with clotting and heart disease. So for a while, MTHFR genotyping was ordered in clinics as part of clotting workups.
Then the larger studies and meta-analyses arrived. The American College of Medical Genetics’ practice guideline reviewed them and concluded that MTHFR polymorphism testing has minimal clinical utility: it recommends against ordering it in evaluations for blood clots or recurrent pregnancy loss, noting that the hypothesized links had not held up. The same guideline notes that knowing your MTHFR status does not change the standard folic-acid advice.
On the supplement question, the CDC is equally direct: people with MTHFR variants can process all types of folate, including ordinary folic acid, and folic-acid intake matters far more for blood folate levels than the variant does. The widely sold idea that a C677T result requires a special methylated vitamin is a marketing claim, not a guideline.
Why the myth survives
MTHFR hype persists because each ingredient is separately true-ish: the enzyme really is less active, homocysteine really is a studied biomarker, folate really does matter in pregnancy. Stacked into a chain of certainties, they produce conclusions the evidence doesn’t support. That pattern (real enzyme, modest effect, inflated story) is worth recognizing, because it recurs across consumer genetics.
What an honest reading looks like
A fair MTHFR report tells you your genotype at C677T (and its companion variant, A1298C), says that the variant is common, states the measured effect on the enzyme, and then says plainly that major guidelines found no routine clinical use for the result. Evigenics reads both variants and presents them exactly that way. If something in your health history makes folate or homocysteine genuinely relevant (pregnancy planning, certain medications), that conversation belongs with a clinician, who will reach for blood tests, not this genotype.
For the habit of mind behind this article, read what your raw file can and cannot tell you and why every reading depends on who was studied.